busulfan has been researched along with Local Neoplasm Recurrence in 94 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 9.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 9.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| " BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)." | 9.15 | Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011) |
| "Double epigenetic modulation of Gem/Bu/Mel with azacitidine/vorinostat is feasible and highly active in patients with refractory/poor-risk relapsed lymphomas, warranting further evaluation." | 7.83 | Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W, 2016) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 7.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma." | 7.74 | Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2008) |
| "Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma." | 7.68 | Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992) |
| " Bu shows wide pharmacokinetic (PK) variability among patients." | 5.62 | Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021) |
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 5.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 5.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| " BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)." | 5.15 | Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011) |
| "Double epigenetic modulation of Gem/Bu/Mel with azacitidine/vorinostat is feasible and highly active in patients with refractory/poor-risk relapsed lymphomas, warranting further evaluation." | 3.83 | Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W, 2016) |
| "Post-relapse survival (PRS) was evaluated in patients with Ewing sarcoma (EWS) enrolled in chemotherapy protocols based on the use of high-dose chemotherapy with busulfan and melfalan (HDT) as a first-line consolidation treatment in high-risk patients." | 3.81 | Post-relapse survival in patients with Ewing sarcoma. ( Abate, ME; Brach del Prever, A; Cammelli, S; DiGirolamo, S; Eriksson, M; Fagioli, F; Ferrari, S; Hall, KS; Luksch, R; Paioli, A; Podda, M; Prete, A; Tamburini, A; Tienghi, A, 2015) |
| "Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML)." | 3.79 | Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia worki ( Aljurf, M; Ben Othman, T; Campos, A; Labopin, M; Masszi, T; Michallet, M; Mohty, M; Nagler, A; Passweg, J; Poire, X; Rocha, V; Sengelov, H; Shimoni, A; Socie, G; Unal, A; Veelken, H; Volin, L; Yakoub-Agha, I, 2013) |
| " The authors report long-term survival of a 1-year-old patient with recurrent CPC and Li-Fraumeni syndrome with surgical resection and high-dose chemotherapy (HDC) consisting of single cycle of Busulfan and Thiotepa followed by autologous stem cell rescue without the use of radiation therapy." | 3.79 | Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue. ( Bartels, U; Bouffet, E; Huang, A; Mosleh, O; Schechter, T; Tabori, U, 2013) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 3.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma." | 3.74 | Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2008) |
| "Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma." | 3.68 | Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992) |
| "Although exposure-directed busulfan (BU) dosing can improve allogeneic hematopoietic stem cell transplantation outcomes, there is still large variability in BU exposure with test dose alone due to changes in BU clearance caused by drug interactions." | 3.30 | Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. ( Akasaka, T; Anzai, N; Arai, Y; Arima, N; Iemura, T; Ikeda, T; Imada, K; Ishikawa, T; Itoh, M; Kanda, J; Kitano, T; Kitawaki, T; Kondo, T; Maeda, T; Matsumoto, K; Moriguchi, T; Nohgawa, M; Takaori-Kondo, A; Takeoka, T; Ueda, A; Ueda, Y; Watanabe, M; Yago, K; Yamashita, K; Yonezawa, A, 2023) |
| "or i." | 2.77 | A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. ( Belau, A; Fuxius, S; Heidrich-Lorsbach, E; Heuser, T; Klare, P; Kölbl, H; Mahner, S; Markmann, S; Oskay-Özcelik, G; Ruhmland, B; Sehouli, J; Sommer, H, 2012) |
| "Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens." | 2.73 | Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. ( Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ, 2007) |
| "Ovarian cancer is seventh most common cancer in women worldwide." | 2.53 | Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. ( Lane, G; Montes, A; Seshadri, S; Wuntakal, R, 2016) |
| "All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT." | 1.91 | Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023) |
| " We evaluated two myeloablative conditioning dosing ranges of intravenous (IV) busulfan (Bu) in combination with fludarabine in 70 patients." | 1.91 | Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation. ( Ahmad, S; Edgar, CM; Guo, M; Mcvey, CP; Mori, S; Patel, RD; Rivera-Robles, N; Varela, JC; Yi, F, 2023) |
| " Bu shows wide pharmacokinetic (PK) variability among patients." | 1.62 | Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021) |
| "For patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), total body irradiation (TBI) has been particularly advocated as a part of the conditioning regimen in case of extramedullary involvement in sanctuary sites such as the central nervous system (CNS), to ensure greater tissue penetration." | 1.62 | Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement. ( Behfar, M; Enshaei, M; Esfandbod, M; Hamidieh, AA; Kabootari, M; Monzavi, SM, 2021) |
| " At our institution, Bu was previously administered with fixed weight-based dosing (WBD) in combination with cyclophosphamide (Cy) and etoposide (E) for patients with non-Hodgkin lymphoma (NHL) undergoing autologous stem cell transplantation (ASCT)." | 1.56 | Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Bolwell, B; Copelan, EA; Dean, RM; Gerds, AT; Hamilton, BK; Hill, BT; Jagadeesh, D; Kalaycio, ME; Lucena, M; Majhail, NS; Pohlman, B; Rybicki, LA; Sobecks, RM; Urban, TA, 2020) |
| "Primary refractory acute myeloid leukemia (AML) is associated with a dismal prognosis." | 1.51 | Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. ( Amit, O; Avivi, I; Chemnitz, JM; Hallek, M; Holtick, U; Moshe, Y; Ram, R; Scheid, C; Wolf, D, 2019) |
| "Outcome of children with acute lymphoblastic leukemia (ALL) has improved over the years, but not for those with multiple recurrences because of high therapy resistance and heavily pretreated history that potentially cause physical damages." | 1.43 | Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia. ( Aoki, Y; Imai, K; Ishiwata, Y; Kajiwara, M; Miyawaki, R; Mizutani, S; Morio, T; Takagi, M; Tomizawa, D; Yasuhara, M, 2016) |
| " In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI." | 1.40 | Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. ( Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014) |
| "We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT." | 1.37 | Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. ( Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V, 2011) |
| "We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m(2) body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation." | 1.32 | Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. ( Bojko, P; Dirsch, O; Hilger, RA; Ruehm, SG; Scheulen, ME; Seeber, S, 2003) |
| " Pharmacokinetic analyses of treosulfan were carried on plasma and urine samples from 20 i." | 1.31 | Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. ( Baumgart, J; Hilger, RA; Jacek, G; Kredtke, S; Oberhoff, C; Scheulen, ME; Seeber, S, 2000) |
| " To our knowledge, this is one of the few cases of ROC in which partial remissions using conventionally dosed chemotherapy were achieved repeatedly despite a unfavorable relapse-free interval after high-dose chemotherapy for primary disease." | 1.31 | Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. ( Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT, 2002) |
| "The effectiveness of the treatment on metastasis was also shown by the prolongation of mean survival time in groups of mice which showed no local recurrence of tumors." | 1.27 | Therapeutic effects of PS-K and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice. ( Hosokawa, M; Kobayashi, H; Mizukoshi, T; Sugawara, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.45) | 18.7374 |
| 1990's | 11 (11.70) | 18.2507 |
| 2000's | 20 (21.28) | 29.6817 |
| 2010's | 26 (27.66) | 24.3611 |
| 2020's | 30 (31.91) | 2.80 |
| Authors | Studies |
|---|---|
| Jurkovic Mlakar, S | 1 |
| Uppugunduri, SCR | 1 |
| Nava, T | 1 |
| Mlakar, V | 1 |
| Golay, H | 1 |
| Robin, S | 1 |
| Waespe, N | 1 |
| Rezgui, MA | 1 |
| Chalandon, Y | 1 |
| Boelens, JJ | 1 |
| Bredius, RGM | 1 |
| Dalle, JH | 1 |
| Peters, C | 1 |
| Corbacioglu, S | 1 |
| Bittencourt, H | 1 |
| Krajinovic, M | 1 |
| Ansari, M | 1 |
| Esfandbod, M | 1 |
| Enshaei, M | 1 |
| Monzavi, SM | 1 |
| Kabootari, M | 1 |
| Behfar, M | 1 |
| Hamidieh, AA | 1 |
| Sapelli, J | 1 |
| Filho, JS | 1 |
| Matias Vieira, GM | 1 |
| Moura, FL | 1 |
| Germano, JN | 1 |
| de Lima, VCC | 1 |
| Yeh, AC | 1 |
| O'Donnell, PV | 1 |
| Schoch, G | 1 |
| Martin, PJ | 1 |
| McFarland, C | 1 |
| McCune, JS | 1 |
| Cooper, JP | 1 |
| Doney, K | 1 |
| Flowers, MED | 1 |
| Sorror, ML | 1 |
| Appelbaum, FR | 1 |
| Storer, BE | 1 |
| Gooley, T | 2 |
| Deeg, HJ | 2 |
| Kurosawa, S | 1 |
| Shimomura, Y | 2 |
| Itonaga, H | 1 |
| Najima, Y | 1 |
| Kobayashi, T | 1 |
| Ozawa, Y | 1 |
| Kanda, Y | 1 |
| Kako, S | 1 |
| Kawakita, T | 1 |
| Matsuoka, KI | 2 |
| Maruyama, Y | 1 |
| Ota, S | 1 |
| Nakazawa, H | 2 |
| Imada, K | 2 |
| Kimura, T | 1 |
| Kanda, J | 2 |
| Fukuda, T | 2 |
| Atsuta, Y | 3 |
| Ishiyama, K | 1 |
| Braitsch, K | 1 |
| Schwarz, A | 1 |
| Koch, K | 1 |
| Hubbuch, M | 1 |
| Menzel, H | 1 |
| Keller, U | 1 |
| Götze, KS | 1 |
| Bassermann, F | 1 |
| Herhaus, P | 1 |
| Verbeek, M | 1 |
| Ali, N | 1 |
| Sharma, AA | 1 |
| de Rezende, ACP | 1 |
| Otegbeye, F | 1 |
| Latif, BM | 1 |
| Kerbauy, MN | 1 |
| Cooper, BW | 1 |
| Sanchez, G | 1 |
| Metheny, L | 1 |
| Bal, SK | 1 |
| Sakuraba, R | 1 |
| Tomlinson, BK | 1 |
| Boughan, KM | 1 |
| Kerbauy, L | 1 |
| Malek, E | 1 |
| Ribeiro, AF | 1 |
| Gallogly, M | 1 |
| Mansur, D | 1 |
| Pereira, G | 1 |
| Weltman, E | 1 |
| Sekaly, RP | 1 |
| de Lima, M | 1 |
| Caimi, PF | 1 |
| Hamerschlak, N | 1 |
| Schenone, L | 1 |
| Houillier, C | 1 |
| Tanguy, ML | 1 |
| Choquet, S | 3 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 1 |
| Schmitt, A | 1 |
| Bouabdallah, K | 2 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 1 |
| Fornecker, LM | 1 |
| Chinot, O | 1 |
| Peyrade, F | 1 |
| Bouabdallah, R | 2 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 2 |
| Oberic, L | 1 |
| Delwail, V | 1 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 4 |
| Taillandier, L | 2 |
| Soussain, C | 4 |
| Cohen, IJ | 1 |
| Ash, S | 1 |
| Andersson, BS | 5 |
| Thall, PF | 2 |
| Ma, J | 1 |
| Valdez, BC | 2 |
| Bassett, R | 1 |
| Chen, J | 2 |
| Ahmed, S | 3 |
| Alousi, A | 2 |
| Bashir, Q | 2 |
| Ciurea, S | 1 |
| Gulbis, A | 2 |
| Cool, R | 1 |
| Kawedia, J | 1 |
| Hosing, C | 2 |
| Kebriaei, P | 1 |
| Kornblau, S | 1 |
| Myers, A | 2 |
| Oran, B | 1 |
| Rezvani, K | 1 |
| Shah, N | 2 |
| Shpall, E | 1 |
| Parmar, S | 1 |
| Popat, UR | 1 |
| Nieto, Y | 2 |
| Champlin, RE | 3 |
| Xu, L | 2 |
| Lu, Y | 1 |
| Hu, S | 1 |
| Li, C | 1 |
| Tang, Y | 1 |
| Wang, H | 1 |
| Yan, J | 1 |
| Liu, S | 1 |
| Sun, Y | 1 |
| Wu, X | 1 |
| Lin, F | 1 |
| Lu, P | 1 |
| Huang, X | 2 |
| Zhang, W | 1 |
| Gui, R | 1 |
| Zu, Y | 1 |
| Zhang, B | 1 |
| Li, Z | 1 |
| Zhang, Y | 1 |
| Wang, X | 1 |
| Guo, S | 1 |
| Zhan, X | 1 |
| Fu, Y | 1 |
| Song, Y | 1 |
| Zhou, J | 1 |
| Firsova, MV | 1 |
| Mendeleeva, LP | 1 |
| Parovichnikova, EN | 1 |
| Solovev, MV | 1 |
| Kuzmina, LA | 1 |
| Risinskaya, NV | 1 |
| Abramova, TV | 1 |
| Galtseva, IV | 1 |
| Savchenko, VG | 1 |
| Choi, Y | 1 |
| Choi, EJ | 1 |
| Park, HS | 1 |
| Lee, JH | 2 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Woo, JM | 1 |
| Kang, H | 1 |
| Baek, S | 1 |
| Kim, SM | 1 |
| Bong, CE | 1 |
| Lee, KH | 1 |
| Tannumsaeung, S | 3 |
| Anurathapan, U | 3 |
| Pakakasama, S | 3 |
| Pongpitcha, P | 3 |
| Songdej, D | 3 |
| Sirachainan, N | 3 |
| Hongeng, S | 3 |
| Mori, S | 3 |
| Guo, M | 3 |
| Rivera-Robles, N | 3 |
| Edgar, CM | 3 |
| Mcvey, CP | 3 |
| Yi, F | 3 |
| Ahmad, S | 3 |
| Patel, RD | 3 |
| Varela, JC | 3 |
| Kamijo, K | 1 |
| Shinohara, A | 1 |
| Mizuno, S | 2 |
| Kanaya, M | 1 |
| Usui, Y | 1 |
| Kim, SW | 2 |
| Ara, T | 1 |
| Mizuno, I | 1 |
| Kuriyama, T | 1 |
| Kusumoto, S | 1 |
| Maseki, N | 1 |
| Yamaguchi, M | 1 |
| Ashida, T | 1 |
| Onizuka, M | 1 |
| Kondo, E | 1 |
| Iemura, T | 1 |
| Kondo, T | 1 |
| Ueda, A | 1 |
| Maeda, T | 1 |
| Kitawaki, T | 1 |
| Arai, Y | 1 |
| Ikeda, T | 2 |
| Ishikawa, T | 1 |
| Anzai, N | 1 |
| Itoh, M | 1 |
| Takeoka, T | 1 |
| Akasaka, T | 1 |
| Yago, K | 1 |
| Yonezawa, A | 1 |
| Arima, N | 1 |
| Kitano, T | 1 |
| Nohgawa, M | 1 |
| Watanabe, M | 2 |
| Moriguchi, T | 1 |
| Yamashita, K | 1 |
| Ueda, Y | 1 |
| Matsumoto, K | 2 |
| Takaori-Kondo, A | 1 |
| Sevrin, F | 1 |
| Kolesnikov-Gauthier, H | 1 |
| Cougnenc, O | 1 |
| Bogart, E | 1 |
| Schleiermacher, G | 1 |
| Courbon, F | 1 |
| Gambart, M | 1 |
| Giraudet, AL | 1 |
| Corradini, N | 1 |
| Badel, JN | 1 |
| Rault, E | 1 |
| Oudoux, A | 1 |
| Deley, MCL | 1 |
| Valteau-Couanet, D | 3 |
| Defachelles, AS | 1 |
| Shimoni, A | 2 |
| Hill, BT | 1 |
| Rybicki, LA | 1 |
| Urban, TA | 1 |
| Lucena, M | 1 |
| Jagadeesh, D | 1 |
| Gerds, AT | 1 |
| Dean, RM | 1 |
| Sobecks, RM | 1 |
| Pohlman, B | 1 |
| Bolwell, B | 1 |
| Kalaycio, ME | 1 |
| Hamilton, BK | 1 |
| Copelan, EA | 2 |
| Majhail, NS | 1 |
| Al-Mofareh, M | 1 |
| Ayas, M | 1 |
| Al-Seraihy, A | 1 |
| Siddiqui, K | 1 |
| Al-Jefri, A | 1 |
| Ghemlas, I | 1 |
| Alsaedi, H | 1 |
| El-Solh, H | 1 |
| Al-Sweedan, S | 1 |
| Al-Saud, B | 1 |
| Al-Mousa, H | 1 |
| Al-Dhekri, H | 1 |
| Arnaout, R | 1 |
| Mohammed, R | 1 |
| Al-Muhsen, S | 1 |
| Al-Ahmari, A | 1 |
| Felber, M | 1 |
| Steward, CG | 1 |
| Kentouche, K | 1 |
| Fasth, A | 1 |
| Wynn, RF | 1 |
| Zeilhofer, U | 1 |
| Haunerdinger, V | 1 |
| Volkmer, B | 1 |
| Prader, S | 1 |
| Gruhn, B | 1 |
| Ehl, S | 1 |
| Lehmberg, K | 1 |
| Müller, D | 1 |
| Gennery, AR | 1 |
| Albert, MH | 1 |
| Hauck, F | 1 |
| Rao, K | 1 |
| Veys, P | 1 |
| Hassan, M | 1 |
| Lankester, AC | 1 |
| Schmid, JP | 1 |
| Hauri-Hohl, MM | 1 |
| Güngör, T | 1 |
| Ousia, S | 1 |
| Kalra, A | 1 |
| Williamson, TS | 1 |
| Prokopishyn, N | 1 |
| Dharmani-Khan, P | 1 |
| Khan, FM | 1 |
| Jimenez-Zepeda, V | 1 |
| Jamani, K | 1 |
| Duggan, PR | 1 |
| Daly, A | 1 |
| Russell, JA | 1 |
| Storek, J | 1 |
| Epperla, N | 1 |
| Ahn, KW | 1 |
| Khanal, M | 1 |
| Litovich, C | 1 |
| Ghosh, N | 1 |
| Fenske, TS | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sureda, A | 1 |
| Hamadani, M | 1 |
| Rasor, B | 1 |
| Dickerson, T | 1 |
| Zhao, Q | 1 |
| Elder, P | 1 |
| Brammer, JE | 1 |
| Larkin, K | 1 |
| Jaglowski, S | 1 |
| Mims, A | 1 |
| Penza, S | 1 |
| Vasu, S | 1 |
| Wall, SA | 1 |
| William, B | 1 |
| Saad, A | 1 |
| Roddy, JVF | 1 |
| Choe, H | 1 |
| Puto, M | 1 |
| Takahashi, M | 1 |
| Sumitani, R | 1 |
| Hori, T | 1 |
| Murai, J | 1 |
| Kawata, S | 1 |
| Oura, M | 1 |
| Sogabe, K | 1 |
| Harada, T | 1 |
| Fujii, S | 1 |
| Miki, H | 1 |
| Kagawa, K | 1 |
| Abe, M | 1 |
| Nakamura, S | 1 |
| Jondreville, L | 1 |
| Roos-Weil, D | 1 |
| Uzunov, M | 1 |
| Boussen, I | 1 |
| Grenier, A | 1 |
| Norol, F | 1 |
| Morel, V | 1 |
| Nguyen, S | 1 |
| Souchet, L | 1 |
| Ji, J | 1 |
| Liu, Z | 1 |
| Kuang, P | 1 |
| Dong, T | 1 |
| Chen, X | 1 |
| Li, J | 1 |
| Zhang, C | 2 |
| Liu, J | 1 |
| Zhang, L | 1 |
| Shen, K | 1 |
| Liu, T | 1 |
| Bramanti, S | 1 |
| De Philippis, C | 1 |
| Bartoli, A | 1 |
| Giordano, L | 1 |
| Mariotti, J | 1 |
| Sarina, B | 1 |
| Mannina, D | 1 |
| Valli, V | 1 |
| De Gregori, S | 1 |
| Roperti, M | 1 |
| Pieri, G | 1 |
| Castagna, L | 1 |
| Ram, R | 1 |
| Scheid, C | 1 |
| Amit, O | 1 |
| Chemnitz, JM | 1 |
| Moshe, Y | 1 |
| Hallek, M | 1 |
| Wolf, D | 1 |
| Avivi, I | 1 |
| Holtick, U | 1 |
| Nagler, A | 3 |
| Rocha, V | 1 |
| Labopin, M | 2 |
| Unal, A | 1 |
| Ben Othman, T | 1 |
| Campos, A | 1 |
| Volin, L | 1 |
| Poire, X | 1 |
| Aljurf, M | 1 |
| Masszi, T | 1 |
| Socie, G | 1 |
| Sengelov, H | 1 |
| Michallet, M | 2 |
| Passweg, J | 1 |
| Veelken, H | 1 |
| Yakoub-Agha, I | 1 |
| Mohty, M | 3 |
| Gao, L | 2 |
| Gong, Y | 1 |
| Chen, XH | 1 |
| Zhang, X | 2 |
| Kato, K | 2 |
| Yoshida, N | 1 |
| Matsuyama, T | 1 |
| Welch, MR | 1 |
| Sauter, CS | 1 |
| Matasar, MJ | 1 |
| Faivre, G | 1 |
| Weaver, SA | 1 |
| Moskowitz, CH | 1 |
| Omuro, AM | 1 |
| Fu, H | 1 |
| Liu, D | 2 |
| Liu, K | 1 |
| Chen, H | 1 |
| Chen, Y | 1 |
| Han, W | 1 |
| Wang, Y | 1 |
| Wang, J | 1 |
| Wang, F | 1 |
| Michelagnoli, M | 1 |
| Whelan, J | 1 |
| Forsyth, S | 1 |
| Furst, S | 1 |
| Asselineau, J | 1 |
| Chevalier, P | 1 |
| Tournilhac, O | 1 |
| Ceballos, P | 1 |
| Vigouroux, S | 1 |
| Tabrizi, R | 1 |
| Doussau, A | 1 |
| Le Gouill, S | 1 |
| Blaise, D | 1 |
| Milpied, N | 1 |
| Baron, F | 1 |
| Peniket, A | 1 |
| Jindra, P | 1 |
| Afanasyev, B | 1 |
| Sanz, MA | 1 |
| Deconinck, E | 1 |
| Ishida, H | 1 |
| Adachi, S | 1 |
| Hasegawa, D | 1 |
| Okamoto, Y | 1 |
| Goto, H | 1 |
| Inagaki, J | 1 |
| Inoue, M | 2 |
| Koh, K | 1 |
| Yabe, H | 1 |
| Kawa, K | 1 |
| Kudo, K | 1 |
| Ferrari, S | 1 |
| Luksch, R | 1 |
| Hall, KS | 1 |
| Fagioli, F | 1 |
| Prete, A | 1 |
| Tamburini, A | 1 |
| Tienghi, A | 1 |
| DiGirolamo, S | 1 |
| Paioli, A | 1 |
| Abate, ME | 1 |
| Podda, M | 1 |
| Cammelli, S | 1 |
| Eriksson, M | 1 |
| Brach del Prever, A | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Aoki, Y | 1 |
| Miyawaki, R | 1 |
| Imai, K | 1 |
| Takagi, M | 1 |
| Kajiwara, M | 1 |
| Ishiwata, Y | 1 |
| Yasuhara, M | 1 |
| Morio, T | 1 |
| Mizutani, S | 1 |
| Tomizawa, D | 1 |
| Devine, SM | 1 |
| Owzar, K | 1 |
| Blum, W | 1 |
| Mulkey, F | 1 |
| Stone, RM | 1 |
| Hsu, JW | 1 |
| Chen, YB | 1 |
| Vij, R | 1 |
| Slack, J | 1 |
| Soiffer, RJ | 1 |
| Larson, RA | 1 |
| Shea, TC | 1 |
| Hars, V | 1 |
| Sibley, AB | 1 |
| Giralt, S | 1 |
| Carter, S | 1 |
| Horowitz, MM | 1 |
| Linker, C | 1 |
| Alyea, EP | 1 |
| Versluis, J | 1 |
| Hazenberg, CL | 1 |
| Passweg, JR | 1 |
| van Putten, WL | 1 |
| Maertens, J | 1 |
| Biemond, BJ | 1 |
| Theobald, M | 1 |
| Graux, C | 1 |
| Kuball, J | 1 |
| Schouten, HC | 1 |
| Pabst, T | 1 |
| Löwenberg, B | 1 |
| Ossenkoppele, G | 1 |
| Vellenga, E | 1 |
| Cornelissen, JJ | 1 |
| Jones, RB | 1 |
| Wei, W | 1 |
| Popat, U | 1 |
| Shpall, EJ | 1 |
| Qazilbash, M | 1 |
| Anderlini, P | 1 |
| Oki, Y | 1 |
| Fanale, M | 1 |
| Dabaja, B | 1 |
| Pinnix, C | 1 |
| Champlin, R | 1 |
| Wuntakal, R | 1 |
| Seshadri, S | 1 |
| Montes, A | 1 |
| Lane, G | 1 |
| Maher, OM | 1 |
| Silva, JG | 1 |
| Wu, J | 1 |
| Cooper, LJ | 1 |
| Tarek, N | 1 |
| Worth, L | 1 |
| Lee, DA | 1 |
| Petropoulos, D | 1 |
| Franklin, AR | 1 |
| Zweidler-Mckay, P | 1 |
| Wells, RJ | 1 |
| Rondon, G | 1 |
| Tewari, P | 1 |
| Meier, W | 2 |
| du Bois, A | 1 |
| Reuss, A | 1 |
| Kuhn, W | 1 |
| Olbricht, S | 1 |
| Gropp, M | 2 |
| Richter, B | 1 |
| Lück, HJ | 1 |
| Kimmig, R | 1 |
| Pfisterer, J | 1 |
| Markman, M | 1 |
| Yoon, DH | 1 |
| Lee, DH | 1 |
| Choi, DR | 1 |
| Sohn, BS | 1 |
| Kim, S | 1 |
| Lee, JS | 1 |
| Lee, SW | 1 |
| Huh, J | 1 |
| Suh, C | 1 |
| Farag, SS | 1 |
| Wood, LL | 1 |
| Schwartz, JE | 1 |
| Srivastava, S | 1 |
| Nelson, RP | 1 |
| Robertson, MJ | 1 |
| Abonour, R | 1 |
| Secrest, A | 1 |
| Cox, E | 1 |
| Baute, J | 1 |
| Sullivan, C | 1 |
| Kane, K | 1 |
| Jones, DR | 1 |
| del Rio, MS | 1 |
| Glaisner, S | 1 |
| Fourme, E | 2 |
| Janvier, M | 2 |
| Nagi, W | 1 |
| Lim, ZY | 1 |
| Krishnamurthy, P | 1 |
| Potter, V | 1 |
| Tindell, V | 1 |
| Reiff-Zall, L | 1 |
| Abdullah, A | 1 |
| Lea, N | 1 |
| Kenyon, M | 1 |
| Marsh, J | 1 |
| Ho, AY | 1 |
| Mufti, GJ | 1 |
| Pagliuca, A | 1 |
| Sugito, K | 1 |
| Furuya, T | 1 |
| Kaneda, H | 1 |
| Masuko, T | 1 |
| Ohashi, K | 1 |
| Koshinaga, T | 1 |
| Yagasaki, H | 1 |
| Mugishima, H | 1 |
| Maebayashi, T | 1 |
| Miura, Y | 1 |
| Toyooka, N | 1 |
| Iwai, F | 1 |
| Matsui, Y | 1 |
| Hirai, M | 1 |
| Kaneko, H | 1 |
| Tsudo, M | 1 |
| Mahner, S | 1 |
| Oskay-Özcelik, G | 1 |
| Heidrich-Lorsbach, E | 1 |
| Fuxius, S | 1 |
| Sommer, H | 1 |
| Klare, P | 1 |
| Belau, A | 1 |
| Ruhmland, B | 1 |
| Heuser, T | 1 |
| Kölbl, H | 1 |
| Markmann, S | 1 |
| Sehouli, J | 1 |
| Mosleh, O | 1 |
| Tabori, U | 1 |
| Bartels, U | 1 |
| Huang, A | 1 |
| Schechter, T | 1 |
| Bouffet, E | 2 |
| Di Nicolantonio, F | 1 |
| Neale, MH | 1 |
| Knight, LA | 1 |
| Lamont, A | 1 |
| Skailes, GE | 1 |
| Osborne, RJ | 1 |
| Allerton, R | 1 |
| Kurbacher, CM | 2 |
| Cree, IA | 1 |
| Bojko, P | 1 |
| Hilger, RA | 2 |
| Ruehm, SG | 1 |
| Dirsch, O | 1 |
| Seeber, S | 2 |
| Scheulen, ME | 2 |
| Dreger, P | 2 |
| Brand, R | 1 |
| Hansz, J | 1 |
| Milligan, D | 1 |
| Corradini, P | 1 |
| Finke, J | 1 |
| Deliliers, GL | 1 |
| Martino, R | 1 |
| Russell, N | 1 |
| Van Biezen, A | 1 |
| Niederwieser, D | 1 |
| CLIFFORD, P | 1 |
| BHARDWAJ, BV | 1 |
| WHITTAKER, LR | 1 |
| Claviez, A | 1 |
| Klingebiel, T | 1 |
| Beyer, J | 1 |
| Nürnberger, W | 1 |
| Ehninger, G | 1 |
| Suttorp, M | 1 |
| Dörffel, W | 1 |
| Schmitz, N | 1 |
| Shah, AJ | 1 |
| Lenarsky, C | 1 |
| Kapoor, N | 2 |
| Crooks, GM | 1 |
| Kohn, DB | 1 |
| Parkman, R | 1 |
| Epport, K | 1 |
| Wilson, K | 1 |
| Weinberg, K | 1 |
| Pérez-Martínez, A | 1 |
| Lassaletta, A | 1 |
| González-Vicent, M | 1 |
| Sevilla, J | 1 |
| Díaz, MA | 1 |
| Madero, L | 1 |
| Klein, JP | 1 |
| McTiernan, A | 1 |
| Driver, D | 1 |
| Michelagnoli, MP | 1 |
| Kilby, AM | 1 |
| Whelan, JS | 1 |
| Markova, M | 1 |
| Barker, JN | 1 |
| Miller, JS | 1 |
| Arora, M | 1 |
| Wagner, JE | 1 |
| Burns, LJ | 1 |
| MacMillan, ML | 1 |
| Douek, D | 1 |
| DeFor, T | 1 |
| Tan, Y | 1 |
| Repka, T | 1 |
| Blazar, BR | 1 |
| Weisdorf, DJ | 1 |
| Ridola, V | 1 |
| Grill, J | 2 |
| Doz, F | 3 |
| Gentet, JC | 1 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 2 |
| Kalifa, C | 3 |
| Atzpodien, J | 1 |
| Terfloth, K | 1 |
| Fluck, M | 1 |
| Reitz, M | 1 |
| Witz, F | 1 |
| Dupriez, B | 1 |
| Souleau, B | 1 |
| Taksin, AL | 1 |
| Gisselbrecht, C | 1 |
| Jaccard, A | 1 |
| Omuro, A | 1 |
| Sanson, M | 1 |
| Kolb, B | 1 |
| Zini, JM | 1 |
| Leblond, V | 2 |
| Clift, RA | 1 |
| Buckner, CD | 1 |
| Thomas, ED | 1 |
| Bensinger, WI | 1 |
| Bowden, R | 1 |
| Bryant, E | 1 |
| Doney, KC | 1 |
| Fisher, LD | 1 |
| Hansen, JA | 1 |
| Klumpp, TR | 1 |
| Mangan, KF | 1 |
| Glenn, LD | 1 |
| Macdonald, JS | 1 |
| Salutari, P | 1 |
| Micciulli, G | 1 |
| Chiusolo, P | 1 |
| Tommasi, M | 1 |
| Di Mario, A | 1 |
| Sica, S | 1 |
| Leone, G | 1 |
| Schoepfer, C | 1 |
| Couanet, D | 1 |
| Terrier-Lacombe, MJ | 1 |
| Hartmann, O | 2 |
| Graham, ML | 1 |
| Herndon, JE | 1 |
| Casey, JR | 1 |
| Chaffee, S | 1 |
| Ciocci, GH | 1 |
| Krischer, JP | 1 |
| Kurtzberg, J | 1 |
| Laughlin, MJ | 1 |
| Longee, DC | 1 |
| Olson, JF | 1 |
| Paleologus, N | 1 |
| Pennington, CN | 1 |
| Friedman, HS | 1 |
| Dupuis-Girod, S | 1 |
| Benhamou, E | 1 |
| Mechinaud, F | 1 |
| Coze, C | 1 |
| Varterasian, M | 1 |
| Janakiraman, N | 1 |
| Karanes, C | 1 |
| Abella, E | 1 |
| Uberti, J | 1 |
| Dragovic, J | 1 |
| Raman, SB | 1 |
| al-Katib, A | 1 |
| Du, W | 1 |
| Silver, SM | 1 |
| Adams, PT | 1 |
| Sensenbrenner, L | 1 |
| Ratanatharathorn, V | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Miyamoto, T | 1 |
| Takenaka, K | 1 |
| Tanimoto, K | 1 |
| Fujisaki, T | 1 |
| Nagafuji, K | 1 |
| Hayashi, S | 1 |
| Eto, T | 1 |
| Taniguchi, S | 1 |
| Akashi, K | 1 |
| Harada, N | 1 |
| Yamasaki, K | 1 |
| Shibuya, T | 1 |
| Matsuishi, E | 1 |
| Ohno, Y | 1 |
| Makino, S | 1 |
| Takamatsu, Y | 1 |
| Murakawa, M | 1 |
| Teshima, T | 1 |
| Hirota, Y | 1 |
| Okamura, T | 1 |
| Kinukawa, N | 1 |
| Niho, Y | 1 |
| Hepp, H | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Sanders, J | 1 |
| Slavin, S | 1 |
| Varadi, G | 1 |
| Naparstek, E | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Jacek, G | 1 |
| Oberhoff, C | 1 |
| Kredtke, S | 1 |
| Baumgart, J | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Levy, V | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Schmidt, F | 1 |
| Wick, W | 1 |
| Herrlinger, U | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Breidenbach, M | 1 |
| Rein, DT | 1 |
| Mallmann, P | 1 |
| Keever, CA | 1 |
| Hsu, SH | 1 |
| Tutschka, PJ | 1 |
| Yeager, AM | 1 |
| Vogelsang, GB | 1 |
| Jones, RJ | 1 |
| Farmer, ER | 1 |
| Altomonte, V | 1 |
| Hess, AD | 1 |
| Santos, GW | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Bergsagel, DE | 1 |
| Hosokawa, M | 1 |
| Mizukoshi, T | 1 |
| Sugawara, M | 1 |
| Kobayashi, H | 1 |
| Shershah, S | 1 |
| Thornes, RD | 1 |
| Fox, BW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation[NCT01257854] | 200 participants (Anticipated) | Observational | 2008-02-29 | Recruiting | |||
| Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies[NCT02735824] | 500 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma[NCT03151876] | Phase 2 | 93 participants (Anticipated) | Interventional | 2017-06-12 | Recruiting | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse[NCT04758000] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen[NCT00070135] | Phase 2 | 121 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)[NCT03992352] | 1,229 participants (Actual) | Observational | 2019-07-19 | Active, not recruiting | |||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants who were alive and relapse free at 2 years for all patients. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00070135)
Timeframe: Up to 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 42 |
"Percentage of participants who were alive and relapse free at 2 years for patients who were matched with an unrelated donor for transplant. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.~A relapse is defined as any of the following:~Reappearance of leukemia blasts cells in peripheral blood~>5% blasts in the marrow, not attributable to another cause (e.g., bone marrow regeneration)~If there are no circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥ 1 week later with >5% blasts is necessary to meet the criteria for relapse~The development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid" (NCT00070135)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 40 |
Percentage of patients who died due to causes other than relapse (NCT00070135)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 16 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
3 reviews available for busulfan and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Busulfan; Carcinoma, Ovar | 2016 |
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free | 2003 |
[High-dose chemotherapy in relapse of medulloblastoma in young children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cerebellar Ne | 1997 |
26 trials available for busulfan and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Trans | 2022 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2022 |
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic S | 2023 |
Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan.
Topics: Busulfan; Cyclophosphamide; Drug Monitoring; Hematologic Neoplasms; Hematopoietic Stem Cell Transpla | 2023 |
Phase II study of
Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melph | 2023 |
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan | 2015 |
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2009 |
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Centra | 2011 |
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle | 2011 |
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
Topics: Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents, Alkylating; Busulfan; Constipation | 2012 |
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebel | 2005 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladri | 2007 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bilirubin; Bone Marrow Transplantation; Busulfan; Child; Creatinine; Cyclophospha | 1994 |
Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; | 1993 |
A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1996 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Co | 1997 |
Treosulfan as an effective second-line therapy in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Middle Aged; Neoplasm Recu | 1998 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
Treosulfan chemotherapy for recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Busulfan; | 2000 |
Oral anticoagulant therapy of human cancer.
Topics: Administration, Oral; Anticoagulants; Antineoplastic Agents; Breast Neoplasms; Busulfan; Chlorambuci | 1974 |
65 other studies available for busulfan and Local Neoplasm Recurrence
| Article | Year |
|---|---|
GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
Topics: Adolescent; Biomarkers, Tumor; Busulfan; Cell Line, Tumor; Cell Proliferation; Child; Child, Prescho | 2022 |
Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Diseases; Co | 2021 |
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combi | 2021 |
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic St | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplast | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
New Approaches Promise to Improve Local Ewing Sarcoma Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Disease-Free Survival; Hum | 2022 |
Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
Topics: Bone Marrow; Busulfan; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem C | 2022 |
[Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma].
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoieti | 2021 |
A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
Topics: Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, N | 2023 |
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acut | 2020 |
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Ste | 2020 |
Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohisti | 2020 |
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.
Topics: Animals; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocy | 2020 |
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2020 |
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.
Topics: Adult; Busulfan; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Transplantatio | 2021 |
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2021 |
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combi | 2021 |
FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases.
Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Neop | 2021 |
Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie
Topics: Busulfan; Cyclophosphamide; Feasibility Studies; Graft vs Host Disease; Hematologic Neoplasms; Hemat | 2021 |
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Germany; Graft vs Host Disease; Hematopoietic Stem Cell T | 2019 |
Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia worki
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2013 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2014 |
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2015 |
Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Chimerism; Cyc | 2014 |
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Fe | 2015 |
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality | 2015 |
Post-relapse survival in patients with Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2015 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arabinonucl | 2016 |
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2015 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Chil | 2016 |
Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplan | 2017 |
Chemotherapy: Topotecan or treosulfan--that is the question.
Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; D | 2009 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin | 2011 |
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carbop | 2011 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2011 |
Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carcinoma; Choroid Plexus Neoplasms; Combi | 2013 |
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic | 2002 |
Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Femal | 2003 |
INTENSIVE NITROGEN MUSTARD THERAPY WITH ABDOMINAL AORTIC OCCLUSION IN NASOPHARYNGEAL CARCINOMA.
Topics: Adenocarcinoma; Antineoplastic Agents; Aorta; Aorta, Abdominal; Busulfan; Carcinoma; Carcinoma, Squa | 1965 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Dis | 2004 |
Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2004 |
Modelling competing risks in cancer studies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 2006 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfa | 2006 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Fem | 2008 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1996 |
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1997 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2000 |
Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Busulfan; Do | 2000 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycyt | 2002 |
Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantat | 1992 |
Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyc | 1992 |
High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Tr | 1987 |
Interferon alfa-2b in the management of chronic granulocytic leukemia.
Topics: Adult; Aged; Busulfan; Female; Humans; Interferon Type I; Leukemia, Myeloid; Leukocyte Count; Male; | 1988 |
Therapeutic effects of PS-K and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice.
Topics: Adjuvants, Immunologic; Animals; Busulfan; Female; Methylcholanthrene; Mice; Mice, Inbred C57BL; Neo | 1985 |
Treatment by combined chemotherapy for recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cystadenocarcinoma; Female; Hum | 1985 |
The sensitivity of a Yoshida sarcoma to methylene dimethane sulphonate.
Topics: Alkylating Agents; Animals; Busulfan; Female; Injections, Intraperitoneal; Neoplasm Recurrence, Loca | 1969 |